Background: Cyclophosphamide has transformed the outcome of ANCA-associated vasculitis, but it is highly toxic. Recent studies have suggested that pulsed intravenous cyclophosphamide (pCyc) is an effective alternative with less complications, but may lead to an increased rate of relapse. However, these studies used relatively short courses of treatment with cyclophosphamide. In this study we used a prolonged course of low-dose intravenous cyclophosphamide for 18–24 months for ANCA-associated vasculitis, evaluated the effectiveness of pCyc and analysed the outcome of a prolonged treatment on the rate of relapse. Methods: A retrospective analysis of all the patients treated with pCyc from 1995 to 2002 was performed. Results: Thirty-seven patients were followed for an average of 38 months. Thirty-four of 37 patients (91.9%) achieved complete remission at 3 months. Eight (21%) episodes of relapse occurred in 7 patients. The cyclophosphamide was well tolerated with a low rate of infections (18.9%) and 1 death (2.7%) due to sepsis whilst on cyclophosphamide. Conclusion: In this study, pCyc was effective in achieving rapid remission and had a low complication rate. If prolonged, this treatment may reduce the rate of relapse.

Keywords:
Continuous cyclophosphamide, Pulse cyclophosphamide, ANCA-associated vasculitis
1.
Hewins P, Tervaert JW, Savage CO, Kallenberg CG: Is Wegener’s granulomatosis an autoimmune disease? Curr Opin Rheumatol 2000;12:3–10.
2.
Fauci AS, Katz P, Haynes BF, Wolff SM: Cyclophosphamide therapy of severe systemic necrotizing vasculitis. N Engl J Med 1979;301:235–238.
3.
Fauci AS, Haynes BF, Katz P, Wolff SM: Wegener’s granulomatosis: Prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983;98:76–85.
4.
Andrassy K: Therapeutic modalities in patients with generalized Wegener’s granulomatosis (WG) and related diseases. APMIS 1990;19(suppl):47.
5.
Hoffman GS, Kerr GS, Leavitt RY, et al: Wegener’s granulomatosis: An analysis of 158 patients. Ann Intern Med 1992;116:488–498.
6.
Gaskin G, Pusey CD: Systemic Vasculitis (ch); in AM Davison (ed): Oxford Textbook of Clinical Nephrology, ed 2. Oxford, Oxford University Press, 1998, pp 877–910.
7.
Bansal VK, Beto JA: Treatment of lupus nephritis: A meta-analysis of clinical trials. Am J Kidney Dis 1997 29:193–199.
8.
de Groot K, Adu D, Savage CO: The value of pulse cyclophosphamide in ANCA-associated vasculitis: Meta-analysis and critical review. Nephrol Dial Transplant 2001;16:2018–2027.
9.
Rasmussen N, Wiik A: Indirect immunofluorescence examination for IgG-ANCA in sera. 1st International Workshop on ANCA. APMIS 1989;6(suppl):16–20.
10.
Jennette JC, Falk RJ, Andrassy K, et al: Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;37:187–192.
11.
De’ Oliviera J, Gaskin G, Dash A, Rees AJ, Pusey CD: Relationship between disease activity and anti-neutrophil cytoplasmic antibody concentration in long-term management of systemic vasculitis. Am J Kidney Dis 1995;25:380–389.
12.
Nachman P, Hogan S, Jennette J, Falk R: Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996;7:33–39.
13.
Adu D, Pall A, Luqmani RA: Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. QJM 1997;90:401–409.
14.
Haubitz M, Schellong S, Gobel U, et al: Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: A prospective, randomized study. Arthritis Rheum 1998;41:1835–1844.
15.
Guillevin L, Cordier JF, Lhote F, et al: A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener’s granulomatosis. Arthritis Rheum 1997;40:2187–2198.
16.
Gaskin G, Jayne DR and the European vasculitis study group: Adjunctive plasma exchange is superior to methylprednisolone in acute renal failure due to antinuclear cytoplasm associated glomerulonephritis. Renal Association, Autumn Meeting, London, Oct 2002, p 8.
17.
Jayne D, Rasmussen N, Andrassy K, et al, for the European Vasculitis Study Group: A randomised trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic antibodies. N Engl J Med 2003;349:36–44.
18.
Jayne DR, Chapel H, Adu D, et al: Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 2000;93:433–439.
19.
Nowack R, Gobel U, Klooker P, Hergesell O, Andrassy K, van der Woude: Mycophenolate mofetil for maintenance therapy of Wegener’s granulomatosis and microscopic polyangiitis: A pilot study in 11 patients with renal involvement. J Am Soc Nephrol 1999;10:1965–1971.
20.
Tyndall A, Fassas A, Passweg J, Ruiz de Elvira C, Attal M, Brooks P, et al: Autologous haematopoietic stem cell transplants for autoimmune disease –feasibility and transplant-related mortality. Autoimmune Disease and Lymphoma Working Parties of the European Group for Blood and Marrow Transplantation, the European League Against Rheumatism and the International Stem Cell Project for Autoimmune Disease. Bone Marrow Transplant 1999;24:729–734.
21.
Stone JH, Uhlfelder ML, Hellmann DB, Crook S, Bedocs NM, Hoffman GS: Etanercept combined with conventional treatment in Wegener’s granulomatosis: A six-month open-label trial to evaluate safety. Arthritis Rheum 2001;44:1149–1154.
22.
Booth AD, Jefferson HJ, Ayliffe W, Andrews PA, Jayne DR: Safety and efficacy of TNFalpha blockade in relapsing vasculitis. Ann Rheum Dis 2002;61:559.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.